CF PHARMTECH (02652) shares jumped more than 10% early on Thursday before paring gains to trade 8.23% higher at HK$10.39, with turnover reaching HK$28.74 million. The price surge follows the company's announcement that its self-developed long-acting inhaled powder candidate, ICF001, has received implied clinical trial approvals for three additional indications, completing full coverage across four major indications: PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this class of long-acting inhaled prodrug into clinical trials in China.

Dr. Liang Wenqing, Chairman and Executive Director, stated that the company will simultaneously advance Phase I clinical studies both domestically and internationally, while actively exploring global partnerships, including overseas co-development and regional licensing opportunities. Notably, at the 2026 Xiamen Science and Technology Innovation Industry and Securities Development Conference held on September 6, the company was honored with the "2026 Technology Innovation Golden Bull Award." This prestigious award, recognized as one of the most credible scientific innovation accolades in China's capital market, underscores the company's commitment to high-end pharmaceutical R&D and its robust global strategy, reinforcing its innovative capabilities in the sector.